High Dimensional Cytometric Assay for Clinical Assessment of Vascular Health

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$271,295.00
Award Year:
2013
Program:
SBIR
Phase:
Phase I
Contract:
1R43HL114147-01A1
Award Id:
n/a
Agency Tracking Number:
R43HL114147
Solicitation Year:
2013
Solicitation Topic Code:
NHLBI
Solicitation Number:
PA12-088
Small Business Information
3160 CHESTNUT STREET, SUITE 200, PHILADELPHIA, PA, 19104-
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
965026417
Principal Investigator:
TODD JOHNSON
(859) 323-3162
todd.johnson@cytovas.com
Business Contact:
EMILE MD
(215) 662-3275
Emile.Mohler@uphs.upenn.edu
Research Institution:
Stub




Abstract
DESCRIPTION (provided by applicant): Atherosclerotic disease is a prevalent and progressive condition that can be difficult to assess during sub- clinical stages. A developing and exciting biomarker strategy is the measurement of microparticles (MPs) and assessment of circulating progenitor and mature endothelial cells. All eukaryotic cells shed MPs in response to activation or apoptosis. Elevation of plasma MPs, particularly those of endothelial origin, reflect cellular injury and is a surrogate marker forvascular dysfunction. MPs have been enumerated in a number of conditions where vascular dysfunction and inflammation are important pathophysiological mechanisms, for example coronary artery disease or thrombotic microangiopathies. We recently completed apilot study evaluating levels of MPs in patients with diabetes mellitus and compared flow cytometry results with those of a non cell specific Enzyme Linked ImmunoSorbent assay (ELISA). The ELISA assay results correlated with flow cytometry results but didnot distinguish the cell of origin where the micoparticle originated. Cytovas' overall goal is to develop and validate a novel highthroughput, high content, flow cytometric assay, using a unique biocomputational approach, that will measure cellular and subcellular that provide a signature for individuals at cardiovascular risk. For this study, we will develop the MP component via the following specif aims: 1) Refine the procedures for reproducible detection of MPs using flow cytometry; and 2) Derive a computational analysis paradigm for clinical implementation. Such a high throughput, high information content approach may prove clinically useful for stratifying cardiovascular risk among patients, in guiding and monitoring response to therapy, and in developing new therapeutic and preventive approaches. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: This proposal will provide a new way to manage healthcare for people with, or at risk of, certain heart and blood vessel diseases (such as atherosclerosis). Presently, healthcare for these people relies on the development of symptoms, by which time options are limited. The product that will be developed here will help to evaluate risk before symptoms develop, guide treatment decisions, and assess response to treatment.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government